Haleon (NYSE:HLN - Get Free Report) posted its earnings results on Thursday. The company reported $0.05 earnings per share for the quarter, Zacks reports. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The firm had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.38 billion.
Haleon Price Performance
Shares of HLN traded up $0.41 during trading hours on Monday, hitting $10.59. 7,780,096 shares of the stock were exchanged, compared to its average volume of 6,450,325. The stock's 50-day moving average price is $9.59 and its two-hundred day moving average price is $9.84. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The company has a market cap of $47.94 billion, a price-to-earnings ratio of 31.15, a price-to-earnings-growth ratio of 2.82 and a beta of 0.28. Haleon has a 12-month low of $7.89 and a 12-month high of $10.80.
Haleon Increases Dividend
The company also recently declared a -- dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be paid a $0.1166 dividend. The ex-dividend date is Friday, April 25th. This is a positive change from Haleon's previous -- dividend of $0.05. This represents a dividend yield of 1.6%. Haleon's payout ratio is currently 58.97%.
Analysts Set New Price Targets
A number of research analysts have weighed in on the stock. Sanford C. Bernstein downgraded shares of Haleon from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 8th. Morgan Stanley cut Haleon from an "overweight" rating to an "equal weight" rating in a report on Friday, January 10th. Three research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $10.95.
Check Out Our Latest Research Report on HLN
About Haleon
(
Get Free Report)
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
Featured Stories
Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
